Fred Hutchinson Cancer Center: Lymphoma trials

The registry lists 87 Lymphoma studies with Fred Hutchinson Cancer Center as lead sponsor. 0 are open to participants now and 41 have results posted.

Phase 1 30Phase 2 59Phase 3 2No phase 12(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced ThrombocytopeniaTerminatedNCT03195010Phase 2Results posted
• JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaTerminatedNCT02706405Phase 1Results posted
• Anti-CD20 Radioimmunotherapy Before Chemotherapy and Stem Cell Transplant in Treating Patients With High-Risk B-Cell MalignanciesTerminatedNCT02483000Phase 1Results posted
• Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid MalignanciesCompletedNCT01921387Phase 1/2Results posted
• Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic LeukemiaCompletedNCT01865617Phase 1/2Results posted
• Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid MalignanciesTerminatedNCT01678443Phase 1Results posted
• Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological MalignanciesCompletedNCT01527045Phase 2Results posted
• High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell LymphomaTerminatedNCT01434472Phase 2Results posted
• Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesCompletedNCT01427881Phase 2Results posted
• Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell TransplantTerminatedNCT01419795Phase 2Results posted
• Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell TransplantCompletedNCT01251575Phase 2Results posted
• Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem CellsCompletedNCT01097057Phase 2Results posted
• Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTerminatedNCT01076270Not applicableResults posted
• Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesTerminatedNCT01028716Phase 2Results posted
• Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic LeukemiaCompletedNCT01008462Phase 2Results posted
• Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin LymphomaCompletedNCT00992446Phase 2Results posted
• Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00918723Phase 1/2Results posted
• Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell LymphomaCompletedNCT00867529Phase 2Results posted
• Iodine I 131 Monoclonal Antibody BC8 Before Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaTerminatedNCT00860171Phase 1Results posted
• Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell TransplantCompletedNCT00795769Phase 2Results posted
• Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic CancerCompletedNCT00789776Phase 1/2Results posted
• Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic CancerCompletedNCT00723099Phase 2Results posted
• Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic DiseaseCompletedNCT00719888Phase 2Results posted
• Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other DiseaseTerminatedNCT00719849Phase 2Results posted
• Tositumomab and Iodine I 131 Tositumomab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in First RemissionCompletedNCT00476047Phase 2Results posted
• Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell TransplantCompletedNCT00408681Not applicableResults posted
• Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin LymphomaCompletedNCT00244855Phase 2Results posted
• Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00119392Phase 2Results posted
• Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00118352Phase 2Results posted
• Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
• Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00105001Phase 2Results posted
• Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00104858Phase 2Results posted
• Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell TransplantCompletedNCT00096161Phase 2Results posted
• Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerCompletedNCT00089011Phase 2Results posted
• Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00075478Phase 3Results posted
• Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00073918Phase 2Results posted
• Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid MalignanciesCompletedNCT00072514Phase 2Results posted
• Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell TransplantCompletedNCT00068718Phase 1/2Results posted
• Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancerCompletedNCT00049504Phase 2Results posted
• Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological MalignanciesCompletedNCT00040846Phase 2Results posted
• Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory LymphomaCompletedNCT00005803Phase 1/2Results posted
• Interferon-Beta-1a (FP-1201) to Prevent Toxicities After CD19-Directed CAR T-Cell TherapyWithdrawnNCT05936229Phase 1/2
• Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT05228249Phase 1
• Interactive Survivorship Program for the Improvement of Healthcare Resources in Adolescent and Young Adult Cancer Survivors, INSPIRE-AYA StudyCompletedNCT04593277Not applicable
• Survivorship Care Plans and Telehealth Education for the Improvement of Access to Cancer Survivorship, the IMPACT StudyCompletedNCT04081779Not applicable
• Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in UgandaTerminatedNCT03864419Phase 1
• Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell TransplantationWithdrawnNCT03602898Phase 2
• huJCAR014 CAR-T Cells in Treating Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic LeukemiaTerminatedNCT03103971Phase 1
• Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell TransplantWithdrawnNCT02662296Phase 2
• Gene-Modified HIV-Protected Stem Cell Transplant in Treating Patients With HIV-Associated LymphomaWithdrawnNCT02378922Phase 1
• HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV InfectionWithdrawnNCT02343666Phase 1
• Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin LymphomaWithdrawnNCT01769911Not applicable
• CD19 CAR T Cells for B Cell Malignancies After Allogeneic TransplantCompletedNCT01475058Phase 1/2
• Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell TransplantWithdrawnNCT00833534Phase 2
• Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin LymphomaCompletedNCT00621452Phase 1
• Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00489203Phase 2
• Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell TransplantCompletedNCT00410657Phase 2
• A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic MalignanciesCompletedNCT00343798Phase 1
• Total-Body Irradiation and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer and Other DiseasesCompletedNCT00317785Phase 2
• Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid CancerCompletedNCT00248430Phase 1/2
• Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic CancerCompletedNCT00126477
• Donor Bone Marrow Transplant in Treating Young Patients With Cancer or a Non-Cancerous DiseaseCompletedNCT00118326Phase 1/2
• Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00110071Phase 1
• Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00098566
• Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantationCompletedNCT00096096Phase 2
• Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell TransplantationCompletedNCT00089037Phase 1/2
• Study of the Emotional Needs of Caregivers of Stem Cell Transplantation PatientsCompletedNCT00082654Not applicable
• Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell TransplantCompletedNCT00078858Phase 1/2
• Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00073931Phase 2
• Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic CancerCompletedNCT00062140Phase 1
• Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or LymphomaCompletedNCT00027937Phase 2
• Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerCompletedNCT00027820Phase 1/2
• Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic MalignanciesCompletedNCT00014235Not applicable
• Biological Therapy After Chemotherapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT00012207Phase 1
• Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or ColonCompletedNCT00010283Phase 1/2
• Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic CancerCompletedNCT00006251Phase 1/2
• Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Low- or Intermediate-Grade Non-Hodgkin's LymphomaCompletedNCT00006241Phase 2
• Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00005854Phase 2
• Bone Marrow Transplantation in Treating Patients With Hematologic CancerCompletedNCT00005804Phase 2
• Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerCompletedNCT00005799Not applicable
• Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid TumorsCompletedNCT00004157Phase 2
• Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Nonmalignant Hematologic DiseaseCompletedNCT00003913Phase 2
• Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell TransplantationCompletedNCT00003887Phase 2
• Monoclonal Antibody Therapy in Treating Patients With Lymphoma or LeukemiaCompletedNCT00003874Phase 1/2
• Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple MyelomaCompletedNCT00003196Not applicable
• Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic CancerCompletedNCT00002553Phase 2
• Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow TransplantationCompletedNCT00002456Phase 3